Molecular Oncology
Volume 1, Issue 4 , Pages 425-430 , April 2008

Gene expression signature associated with BRAF mutations in human primary cutaneous melanomas

  • Caroline Kannengiesser

      Affiliations

    • Service de Génétique & CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    • ,
  • Alain Spatz

      Affiliations

    • Department of BioPathology, Institut Gustave Roussy, Villejuif, France
    • Corresponding Author InformationCorresponding author. Department of BioPathology, Institut Gustave Roussy, 94805 Villejuif Cedex, France. Tel.: +33 1 4211 4520; fax: +33 1 4211 5263.
    • ,
  • Stefan Michiels

      Affiliations

    • Division of Biostatistics & Epidemiology, Institut Gustave Roussy, Villejuif, France
    • ,
  • Alain Eychène

      Affiliations

    • Institut Curie, Centre de Recherche & CNRS UMR 146, Orsay, France
    • ,
  • Philippe Dessen

      Affiliations

    • CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    • ,
  • Vladimir Lazar

      Affiliations

    • Division of Functional Genomics, Institut Gustave Roussy, Villejuif, France
    • ,
  • Véronique Winnepenninckx

      Affiliations

    • Department of Morphology and Molecular Pathology, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    • Present address: Department of Pathology, Academic Hospital, University of Maastricht, Maastricht, The Netherlands.
    • ,
  • Fabienne Lesueur

      Affiliations

    • Service de Génétique & CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    • ,
  • Sabine Druillennec

      Affiliations

    • Institut Curie, Centre de Recherche & CNRS UMR 146, Orsay, France
    • ,
  • Caroline Robert

      Affiliations

    • Service de Dermatologie, Institut Gustave Roussy, Villejuif, France
    • ,
  • Joost J. van den Oord

      Affiliations

    • Department of Morphology and Molecular Pathology, University Hospitals, Katholieke Universiteit Leuven, Leuven, Belgium
    • ,
  • Alain Sarasin

      Affiliations

    • CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    • ,
  • Brigitte Bressac-de Paillerets

      Affiliations

    • Service de Génétique & CNRS FRE 2939, Institut Gustave Roussy, Villejuif, France
    • ,
  • On behalf of the EORTC Melanoma group

Received 28 November 2007 ,Revised 31 December 2007 ,Accepted 7 January 2008.

References 

  1. Bloethner S, Hemminki K, Thirumaran RK, Chen B, Mueller-Berghaus J, Ugurel S, et al. Differences in global gene expression in melanoma cell lines with and without homozygous deletion of the CDKN2A locus genes. Melanoma Res. 2006;16:297–307
  2. Buchholz M, Biebl A, Neesse A, Wagner M, Iwamura T, Leder G, et al. SERPINE2 (protease nexin I) promotes extracellular matrix production and local invasion of pancreatic tumors in vivo. Cancer Res. 2003;63:4945–4951
  3. Cao MG, Auge JM, Molina R, Marti R, Carrera C, Castel T, et al. Melanoma inhibiting activity protein (MIA), beta-2 microglobulin and lactate dehydrogenase (LDH) in metastatic melanoma. Anticancer Res. 2007;27:595–599
  4. Chang DZ, Panageas KS, Osman I, Polsky D, Busam K, Chapman PB. Clinical significance of BRAF mutations in metastatic melanoma. J. Transl. Med. 2004;2:46
  5. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–954
  6. Dong J, Phelps RG, Qiao R, Yao S, Benard O, Ronai Z, et al. BRAF oncogenic mutations correlate with progression rather than initiation of human melanoma. Cancer Res. 2003;63:3883–3885
  7. Dumaz N, Hayward R, Martin J, Ogilvie L, Hedley D, Curtin JA, et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 2006;66:9483–9491
  8. Elsner L, Muppala V, Gehrmann M, Lozano J, Malzahn D, Bickeboller H, et al. The heat shock protein HSP70 promotes mouse NK cell activity against tumors that express inducible NKG2D ligands. J. Immunol. 2007;179:5523–5533
  9. Gesierich S, Paret C, Hildebrand D, Weitz J, Zgraggen K, Schmitz-Winnenthal FH, et al. Colocalization of the tetraspanins, CO-029 and CD151, with integrins in human pancreatic adenocarcinoma: impact on cell motility. Clin. Cancer Res. 2005;11:2840–2852
  10. Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, et al. Molecular classification of papillary thyroid carcinoma: distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 2005;24:6646–6656
  11. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006;19:290–302
  12. Iida J, Skubitz AP, McCarthy JB, Skubitz KM. Protein kinase activity is associated with CD63 in melanoma cells. J. Transl. Med. 2005;3:42
  13. Jackson S, Harland M, Turner F, Taylor C, Chambers PA, Randerson-Moor J, et al. No evidence for BRAF as a melanoma/nevus susceptibility gene. Cancer Epidemiol. Biomarkers Prev. 2005;14:913–918
  14. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. Pigment Cell Res. 2007;20:216–221
  15. Kidd M, Modlin IM, Mane SM, Camp RL, Eick G, Latich I. The role of genetic markers—NAP1L1, MAGE-D2, and MTA1—in defining small-intestinal carcinoid neoplasia. Ann. Surg. Oncol. 2006;13:253–262
  16. Kim IJ, Kang HC, Jang SG, Ahn SA, Yoon HJ, Park JG. Development and applications of a BRAF oligonucleotide microarray. J. Mol. Diagn. 2007;9:55–63
  17. Korn EL, Li MC, McShane LM, Simon R. An investigation of two multivariate permutation methods for controlling the false discovery proportion. Stat. Med. 2007;26:4428–4440
  18. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, Pyrhonen S, et al. BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin. Cancer Res. 2003;9:3362–3368
  19. Kumar R, Angelini S, Snellman E, Hemminki K. BRAF mutations are common somatic events in melanocytic nevi. J. Invest. Dermatol. 2004;122:342–348
  20. Lang J, Boxer M, MacKie R. Absence of exon 15 BRAF germline mutations in familial melanoma. Hum. Mutat. 2003;21:327–330
  21. Latysheva N, Muratov G, Rajesh S, Padgett M, Hotchin NA, Overduin M, et al. Syntenin-1 is a new component of tetraspanin-enriched microdomains: mechanisms and consequences of the interaction of syntenin-1 with CD63. Mol. Cell. Biol. 2006;26:7707–7718
  22. Laud K, Kannengiesser C, Avril MF, Chompret A, Stoppa-Lyonnet D, Desjardins L, et al. BRAF as a melanoma susceptibility candidate gene?. Cancer Res. 2003;63:3061–3065
  23. Lazo PA. Functional implications of tetraspanin proteins in cancer biology. Cancer Sci. 2007;98:1666–1677
  24. Le Naour F, Andre M, Greco C, Billard M, Sordat B, Emile JF, et al. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell. Proteomics. 2006;5:845–857
  25. Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature. 2005;436:720–724
  26. Michaloglou C, Vredeveld LC, Mooi WJ, Peeper DS. BRAF(E600) in benign and malignant human tumours. Oncogene. 2007;2007 [Epub ahead of print]
  27. Omholt K, Platz A, Kanter L, Ringborg U, Hansson J. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin. Cancer Res. 2003;9:6483–6488
  28. Papageorgio C, Brachmann R, Zeng J, Culverhouse R, Zhang W, McLeod H. MAGED2: a novel p53-dissociator. Int. J. Oncol. 2007;31:1205–1211
  29. Pollock PM, Harper UL, Hansen KS, Yudt LM, Stark M, Robbins CM, et al. High frequency of BRAF mutations in nevi. Nat. Genet. 2003;33:19–20
  30. Patton EE, Widlund HR, Kutok JL, Kopani KR, Amatruda JF, Murphey RD, et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr. Biol. 2005;15:249–254
  31. Pavey S, Johansson P, Packer L, Taylor J, Stark M, Pollock PM, et al. Microarray expression profiling in melanoma reveals a BRAF mutation signature. Oncogene. 2004;23:4060–4067
  32. Rothhammer T, Bosserhoff AK. Influence of melanoma inhibitory activity on transforming growth factor-beta signaling in malignant melanoma. Melanoma Res. 2006;16:309–316
  33. Shinozaki M, Fujimoto A, Morton DL, Hoon DS. Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin. Cancer Res. 2004;10:1753–1757
  34. Smalley KS, Herlyn M. Loitering with intent: new evidence for the role of BRAF mutations in the proliferation of melanocytic lesions. J. Invest. Dermatol. 2004;123:xvi–xvii
  35. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J. Natl. Cancer Inst. 2006;98:472–482

PII: S1574-7891(08)00003-3

doi: 10.1016/j.molonc.2008.01.002

Molecular Oncology
Volume 1, Issue 4 , Pages 425-430 , April 2008

Article Tools